Testing Nelfinavir for Anemia in People With Myelofibrosis
Tests the drug nelfinavir for anemia in adults with myelofibrosis.
Plain-language title generated from the registry record
Registry title: Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
Key facts
- Where
- Orange, United StatesSee the site
- Phase
- Phase 1/2
Where in United States
- Chao Family Comprehensive Cancer Center, University of California, IrvineOrange, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of California, Irvine
- Trial code
- NCT07281781
- Record updated
- 26 October 2026
- Original description
This is a phase I/II protocol investigating whether Nelfinavir can improve anemia and lower serum fibrosis biomarkers in Myelofibrosis patients.Read full original descriptionShow less
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
This is a phase I/II protocol investigating whether Nelfinavir can improve anemia and lower serum fibrosis biomarkers in Myelofibrosis patients.
Inclusion: ≥18 years of age; Have a diagnosis of myelofibrosis (MF) according to the 2016 WHO criteria; Has a hemoglobin ≤ 10gm/dL at screening; Serum ferritin ≥ 100; May continue on current MPN treatment, including aspirin, hydroxyurea, interferon-alpha, ruxolitinib, fedratinib, or anagrelide; Peripheral blast count <10% during Screening; Free of other known active or metastatic malignancies other than localized skin cancer; Amenable to blood draws and symptom assessments; Agree to the use of contraceptives. Female subjects of childbearing potential and their male partners, or male subjects who have female partners of childbearing potential, should both use an effective contraception method during the study and continue to use contraception for 60 days after the last dose of study drug.
Exclusion: Currently taking Momelotinib or Pacritinib (these agents are purported to reduce hepcidin); Currently taking any of the contraindicated medications to Nelfinavir listed in section 13.2; Known uncontrolled active viral or bacterial infection; Known HIV+; Known history of allergic reaction to nelfinavir; Significant impairment of major organ or hematopoietic function defined as; Serum creatinine clearance less than 30 ml/min (eGFR); Bilirubin more than 1.5 mg/dl except for Gilbert's disease. ALT or AST more than 2X upper normal limit or has radiologic evidence of liver cirrhosis; Platelets < 50 × 10\^9/L without transfusions; ANC < 0.75 × 10\^9/L without growth factors; Eastern Cooperative Oncology Group (ECOG) questionnaire score of ≥3; Currently pregnant or planning on being pregnant within the study period; Currently breastfeeding.